

Lisi Flores Aguilar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6205988/publications.pdf>

Version: 2024-02-01

97
papers

5,965
citations

71061

41
h-index

76872

74
g-index

101
all docs

101
docs citations

101
times ranked

6760
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 788-801.	2.4	8
2	Reimagining cholinergic therapy for Alzheimer's disease. <i>Brain</i> , 2022, 145, 2250-2275.	3.7	50
3	The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy. <i>Cells</i> , 2022, 11, 16.	1.8	17
4	mTORC2 mediates structural plasticity in distal nociceptive endings that contributes to pain hypersensitivity following inflammation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	6
5	Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	4
6	The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 6023-6037.	4.1	40
7	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5989-6001.	4.1	28
8	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	2.0	27
9	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. <i>Alzheimer's and Dementia</i> , 2021, 17, 605-617.	0.4	17
10	A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology. <i>Neurobiology of Disease</i> , 2021, 148, 105150.	2.1	16
11	Specific Susceptibility to COVID-19 in Adults with Down Syndrome. <i>NeuroMolecular Medicine</i> , 2021, 23, 561-571.	1.8	30
12	Hippocampal hyperactivity in a rat model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2021, 157, 2128-2144.	2.1	28
13	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 621440.	2.2	26
14	Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition. <i>Journal of Neuroinflammation</i> , 2021, 18, 147.	3.1	11
15	Leslie Iversen, a friend of friends and an inspiring light in neuropharmacology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	1
16	Nerve Growth Factor Compromise in Down Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 719507.	1.7	1
17	Editorial: Tau Pathology in Neurological Disorders. <i>Frontiers in Neurology</i> , 2021, 12, 754669.	1.1	2
18	Rita Levi-Montalcini, NGF Metabolism in Health and in the Alzheimer's Pathology. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1331, 119-144.	0.8	2

#	ARTICLE	IF	CITATIONS
19	NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 723-739.	1.2	33
20	eIF2 [±] controls memory consolidation via excitatory and somatostatin neurons. <i>Nature</i> , 2020, 586, 412-416.	13.7	74
21	Connecting the "Dots": From Free Radical Lipid Autoxidation to Cell Pathology and Disease. <i>Chemical Reviews</i> , 2020, 120, 12757-12787.	23.0	61
22	Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. <i>Brain</i> , 2020, 143, 3653-3671.	3.7	59
23	Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6844-6854.	3.3	62
24	Ted Sourkes, Moussa Youdim and I. <i>Journal of Neural Transmission</i> , 2020, 127, 119-123.	1.4	0
25	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	2.2	201
26	Early Long-Term Memory Impairment and Changes in the Expression of Synaptic Plasticity-Associated Genes, in the McGill-R-Thy1-APP Rat Model of Alzheimer's-Like Brain Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 585873.	1.7	9
27	Editorial: The Involvement of NGF in the Alzheimer's Pathology. <i>Frontiers in Neuroscience</i> , 2019, 13, 872.	1.4	4
28	Perturbed mitochondria-ER contacts in live neurons modelling Alzheimer's disease amyloid pathology. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	35
29	The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology. <i>Frontiers in Neuroscience</i> , 2019, 13, 62.	1.4	73
30	A β ² -induced vulnerability propagates via the brain's default mode network. <i>Nature Communications</i> , 2019, 10, 2353.	5.8	58
31	Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 189.	1.6	13
32	Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy. <i>Neurobiology of Disease</i> , 2019, 127, 323-338.	2.1	14
33	Effect of antioxidant supplements on lipid peroxidation levels in primary cortical neuron cultures. <i>Free Radical Biology and Medicine</i> , 2019, 130, 471-477.	1.3	10
34	Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 327-341.	1.2	32
35	Platelets Bioenergetics Screening Reflects the Impact of Brain A β ² Plaque Accumulation in a Rat Model of Alzheimer. <i>Neurochemical Research</i> , 2019, 44, 1375-1386.	1.6	7
36	NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo. <i>Neurobiology of Disease</i> , 2018, 114, 24-30.	2.1	58

#	ARTICLE	IF	CITATIONS
37	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	3.1	79
38	AF710B, an M1/ σ_1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 811-823.	0.4	39
39	Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons. <i>Neurobiology of Aging</i> , 2018, 67, 10-20.	1.5	27
40	Chronic Hippocampal Expression of Notch Intracellular Domain Induces Vascular Thickening, Reduces Glucose Availability, and Exacerbates Spatial Memory Deficits in a Rat Model of Early Alzheimer. <i>Molecular Neurobiology</i> , 2018, 55, 8637-8650.	1.9	12
41	Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology. <i>Molecular Neurobiology</i> , 2018, 55, 3451-3476.	1.9	21
42	Microdose Lithium NPO3 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer's-like Amyloidosis. <i>Current Alzheimer Research</i> , 2018, 15, 1220-1230.	0.7	18
43	Evidence of intraneuronal $A\beta_2$ accumulation preceding tau pathology in the entorhinal cortex. <i>Acta Neuropathologica</i> , 2018, 136, 901-917.	3.9	65
44	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1917-1933.	3.7	1,008
45	Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 69-84.	2.4	40
46	Targeting glutamatergic and cellular prion protein mechanisms of amyloid β_2 -mediated persistent synaptic plasticity disruption: Longitudinal studies. <i>Neuropharmacology</i> , 2017, 121, 231-246.	2.0	26
47	Worsening of memory deficit induced by energy-dense diet in a rat model of early-Alzheimer's disease is associated to neurotoxic $A\beta_2$ species and independent of neuroinflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 731-743.	1.8	28
48	Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome. <i>European Journal of Pharmacology</i> , 2017, 817, 7-19.	1.7	15
49	Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 956-966.	4.0	119
50	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. <i>Journal of Neuroscience</i> , 2017, 37, 12263-12271.	1.7	44
51	Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2017, 108, 307-323.	2.1	66
52	An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. <i>Alzheimer's and Dementia</i> , 2016, 12, 1132-1148.	0.4	75
53	Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model. <i>Scientific Reports</i> , 2016, 6, 34051.	1.6	49
54	Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease. <i>Cerebral Cortex</i> , 2016, 27, 1501-1511.	1.6	39

#	ARTICLE	IF	CITATIONS
55	The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 373-383.	1.2	19
56	The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2015, 13, 53-67.	0.7	57
57	Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 321.	1.0	61
58	Intracellular A β pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. <i>Acta Neuropathologica Communications</i> , 2014, 2, 61.	2.4	84
59	Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 667-678.	1.2	55
60	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. <i>Trends in Neurosciences</i> , 2014, 37, 629-641.	4.2	38
61	Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 338-348.	4.0	127
62	Nerve growth factor metabolic dysfunction in Down's syndrome brains. <i>Brain</i> , 2014, 137, 860-872.	3.7	75
63	Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2249-2262.	1.5	123
64	Modeling Alzheimer's disease in transgenic rats. <i>Molecular Neurodegeneration</i> , 2013, 8, 37.	4.4	144
65	Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. <i>Journal of Neuroinflammation</i> , 2012, 9, 62.	3.1	89
66	Evidence for the accumulation of A β immunoreactive material in the human brain and in transgenic animal models. <i>Life Sciences</i> , 2012, 91, 1141-1147.	2.0	13
67	Impact of the NGF Maturation and Degradation Pathway on the Cortical Cholinergic System Phenotype. <i>Journal of Neuroscience</i> , 2012, 32, 2002-2012.	1.7	83
68	Gangliosides, NGF, Brain Aging and Disease: A Mini-Review with Personal Reflections. <i>Neurochemical Research</i> , 2012, 37, 1256-1260.	1.6	9
69	Cholinergic Involvement in Alzheimer's Disease. A Link with NGF Maturation and Degradation. <i>Journal of Molecular Neuroscience</i> , 2010, 40, 230-235.	1.1	111
70	Increased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1309-1318.	0.9	130
71	Amyloid β -Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 857-869.	0.9	122
72	Impact of Intracellular β -Amyloid in Transgenic Animals and Cell Models. <i>Neurodegenerative Diseases</i> , 2008, 5, 146-148.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Paradoxical Upregulation of Glutamatergic Presynaptic Boutons during Mild Cognitive Impairment. <i>Journal of Neuroscience</i> , 2007, 27, 10810-10817.	1.7	117
74	The Failure in NGF Maturation and its Increased Degradation as the Probable Cause for the Vulnerability of Cholinergic Neurons in Alzheimer's Disease. <i>Neurochemical Research</i> , 2007, 32, 1041-1045.	1.6	66
75	Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6735-6740.	3.3	312
76	Intracellular and Extracellular A β , a Tale of Two Neuropathologies. <i>Brain Pathology</i> , 2005, 15, 66-71.	2.1	66
77	Light and electron microscopic study of the distribution of substance P-immunoreactive fibers and neurokinin-1 receptors in the skin of the rat lower lip. <i>Journal of Comparative Neurology</i> , 2001, 432, 466-480.	0.9	27
78	A β Immunoreactive Material Is Present in Several Intracellular Compartments in Transfected, Neuronally Differentiated, P19 Cells Expressing the Human Amyloid A β -Protein Precursor. <i>Journal of Alzheimer's Disease</i> , 2000, 2, 207-222.	1.2	56
79	Peripheral nerve injury leads to the establishment of a novel pattern of sympathetic fibre innervation in the rat skin. , 2000, 422, 287-296.		56
80	Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes. <i>Journal of Neuroscience</i> , 1999, 19, 2706-2716.	1.7	193
81	Ectopic Substance P and Calcitonin Gene-related Peptide Immunoreactive Fibres in the Spinal Cord of Transgenic Mice Over-expressing Nerve Growth Factor. <i>European Journal of Neuroscience</i> , 1995, 7, 2021-2035.	1.2	47
82	The Pharmacology of Neurotrophic Factors. , 1995, , 241-254.		4
83	Chapter 32: Trophic responses of forebrain cholinergic neurons: a discussion. <i>Progress in Brain Research</i> , 1993, 98, 265-277.	0.9	32
84	[No Title]. <i>British Journal of Psychiatry</i> , 1993, 163, 693-694.	1.7	3
85	Similarities in the ultrastructural distribution of nerve growth factor receptor-like immunoreactivity in cerebellar Purkinje cells of the neonatal and colchicine-treated adult rat. <i>Journal of Comparative Neurology</i> , 1991, 305, 189-200.	0.9	18
86	5-Hydroxytryptamine, substance P, and thyrotropin-releasing hormone in the adult cat spinal cord segment L7: Immunohistochemical and chemical studies. <i>Synapse</i> , 1990, 6, 237-270.	0.6	79
87	Choline acetyltransferase-immunoreactive profiles are presynaptic to primary sensory fibers in the rat superficial dorsal horn. <i>Journal of Comparative Neurology</i> , 1990, 295, 370-384.	0.9	131
88	Cellular and subcellular localization of nerve growth factor receptor-like immunoreactivity in the rat CNS. <i>Neurochemistry International</i> , 1990, 17, 205-213.	1.9	14
89	Ultrastructural and neurochemical analysis of synaptic input to trigemino-thalamic projection neurones in lamina I of the rat: A combined immunocytochemical and retrograde labelling study. <i>Journal of Comparative Neurology</i> , 1989, 285, 467-486.	0.9	21
90	Role of Immunology in Defining Transmitter-Specific Neurons. <i>Immunological Reviews</i> , 1987, 100, 279-306.	2.8	7

#	ARTICLE	IF	CITATIONS
91	Hemicholinium mustard derivatives: Preliminary assesment of cholinergic neurotoxicity. <i>Neurochemical Research</i> , 1986, 11, 1091-1102.	1.6	13
92	Choline Acetyltransferase Activity in the Rat Trigeminal System. <i>Journal of Neurochemistry</i> , 1985, 45, 1027-1029.	2.1	4
93	Immunohistochemical demonstration of some putative neurotransmitters in the lamprey spinal cord and spinal ganglia: 5-hydroxytryptamine-, tachykinin-, and neuropeptide-Y-immunoreactive neurons and fibers. <i>Journal of Comparative Neurology</i> , 1985, 234, 501-522.	0.9	105
94	What's new: Hybridoma technology in immunocytochemistry. <i>BioEssays</i> , 1984, 1, 178-179.	1.2	1
95	The anatomy of the CNS cholinergic neurons. <i>Trends in Neurosciences</i> , 1984, 7, 74-78.	4.2	187
96	Depletion of substance P-containing axons in substantia gelatinosa of patients with diminished pain sensitivity. <i>Nature</i> , 1982, 295, 61-63.	13.7	132
97	Localization of Substance P in Neuronal Pathways. <i>Novartis Foundation Symposium</i> , 1982, , 55-83.	1.2	14